Teresa Bitetti – General Manager, BMS Canada
Teresa Bitetti has a long history with BMS, spanning 3 decades in which she rose up the ranks starting from Senior Director of Abilify Marketing before becoming Sales Vice President…
Aquinox Pharmaceuticals, Inc. commenced operations in 2006 as a spin-off from the University of British Columbia, the BC Cancer Agency, and the Vancouver Coastal Health Research Institute, all organizations with outstanding reputations for world-class research.
Aquinox Pharmaceuticals is a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. We are dedicated to advancing novel therapeutics that we believe will make a clinically meaningful difference in patients’ lives.
Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5′-phosphatase 1, or SHIP1, an enzyme that plays a role in an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of drug candidates that activate SHIP1.
Contact:
Address: Suite 450 – 887 Great Northern Way, Vancouver, BC, Canada, V5T 4T5
Tel.: +1 604 629 9223
Website: http://aqxpharma.com/
Teresa Bitetti has a long history with BMS, spanning 3 decades in which she rose up the ranks starting from Senior Director of Abilify Marketing before becoming Sales Vice President…
Mike Brogan, before taking up the mantle of President at IMS was VP of Business Integration at IMS for a year. Today, he talks about the difficulties he has come…
Dr. Fernand Labrie, long before becoming CEO of EndoCeutics, discovered and developed medical castration with GnRH agonists, a breakthrough treatment that quickly replaced surgical castration back in the early 1980s.…
Minister for Science shares with us how the Canadian Government has taken a different approach to funding innovationand the benefits it has reaped in the pharma industry as a whole…
Gary Goodyear, Minister for Science, shares with us how the Canadian Government has taken a different approach to funding innovation and the benefits it has reaped in the pharma industry…
You have been President of Rx&D since 2004, and have witnessed the market’s development over the years. What have been the most important issues since you started and what are…
See our Cookie Privacy Policy Here